The role of short-term oxygen administration in the prevention of intimal hyperplasia  by Lata, Charu et al.
BASIC RESEARCH STUDIES
From the Society for Vascular SurgeryFrom
V
Supp
Auth
Pres
Su
Rep
Su
St
um
The
to
m
0741
Cop
http
452The role of short-term oxygen administration in the
prevention of intimal hyperplasia
Charu Lata, MBBS, Derrick Green, MD, Jing Wan, MD, Sabita Roy, PhD, and
Steven M. Santilli, MD, PhD, Minneapolis, Minn
Objective: Intimal hyperplasia (IH) is the cause of most failed arteriovenous ﬁstulas (AVFs), resulting in repeat procedures
and leading to increased utilization of scarce health care resources. Our laboratory has previously demonstrated the role of
supplemental oxygen in preventing IH and smooth muscle cell proliferation (SMCp) at an artery-to-graft anastomosis
and at the deployment site of an intra-arterial stent. This study examines the effect of supplemental oxygen in preventing
IH and SMCp in an AVF in a rabbit model.
Methods: Ninety-six rabbits were randomized into four groups: group 1, control; group 2, no surgery with supplemental
oxygen; group 3, AVF without supplemental oxygen; and group 4, AVF with supplemental oxygen. Rabbits receiving
supplemental oxygen received 30% oxygen for up to 42 days. Specimens were collected in all groups at days 1, 3, 7, 21, 42,
and 90. IH and SMCp were measured at the AVF site as well as in the artery and vein proximal and distal to the AVF.
Results: IH was ﬁrst noted at day 7 and signiﬁcantly increased through day 90 at all locations in the nonoxygen-sup-
plemented groups. No signiﬁcant IH was noted in the oxygen-supplemented group at any location or any time point.
SMCp was noted at day 3 through day 21 in the nonoxygen-supplemented group, whereas almost no SMCp was noted in
the oxygen-supplemented group at any location or time point.
Conclusions:Without oxygen supplementation, SMCp begins at day 3 and is no longer noted at day 21 after creation of an
AVF, whereas IH begins by day 7 and increases at least through day 90 after creation of an AVF. Forty-two days of 30%
supplemental oxygen inhibits IH and SCMp after creation of an AVF. These data suggest a role for the short-term
administration of low-dose O2 to prevent both IH and SMCp after creation of an AVF that may prolong patency and
function. (J Vasc Surg 2013;58:452-9.)
Clinical Relevance: Our study demonstrates that intimal hyperplasia (IH) at the site of an arteriovenous ﬁstula (AVF), as
well as IH in the artery proximal to the AVF and IH in the vein distal to the AVF, can be inhibited by the short-term
administration of 30% supplemental oxygen. Given the large numbers of end-stage renal disease patients who undergo
AVF placement and the high failure of AVFs secondary to IH, this study has widespread implications for the treatment of
patients undergoing all forms of arterial and venous interventions and should be translated to the human condition.Vascular access is the “lifeline” for end-stage renal
disease (ESRD) patients who receive hemodialysis. Fol-
lowing the “Fistula First Initiative” launched nationwide in
2004, ﬁstulas are considered the gold standard for establish-
ing access to a patient’s circulatory system to provide life-
sustaining dialysis.1 Complications of vascular access arethe Department of Surgery, University of Minnesota and Minneapolis
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but also a major ﬁscal drain for the ESRD program.
Although arteriovenous ﬁstula (AVF) is the preferred
vascular access, its patency at 1 year is estimated to be
only 62%.2 The most common cause of AVF failure is
thrombosis, usually caused by venous stasis associated
with venous stenotic lesions.3 Data suggest that AVFs fail
secondary to venous stenosis caused by intimal hyperplasia
(IH)4 with cellular proliferation and matrix deposition.5 An
effective method to control IH is currently unknown. We
previously established that vessel wall hypoxia has a causa-
tive role in IH. Our laboratory showed that artery wall
hypoxia plays a critical role in IH and smooth muscle cell
proliferation (SMCp).6-11 Our laboratory also demon-
strated that artery wall hypoxia occurs at an arterial anasto-
mosis, and a return to normal artery wall oxygen
concentration is noted after 42 days. We have also shown
that artery wall hypoxia can be reversed and IH and
SMCp inhibited by the administration of 40% supplemental
oxygen for 42 days immediately after creation of an
artery-to-prosthetic graft anastomosis.8,9 Our work has
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 2 Lata et al 453also revealed that supplemental oxygen can reverse artery
wall hypoxia and prevent IH and SMCp at the deployment
site of an intra-arterial stent.10,11
Semenza12 has demonstrated that hypoxia is the
primary stimulus that modulates the expression of various
proteins that are responsible for mediating angiogenesis,
matrix deposition, cellular proliferation, and migration.
Semenza’s work clearly demonstrates modulating oxygen
delivery to the vessel wall should have an effect on the
development of IH.
Strategies to prevent IH, including pharmacologic
therapy, antioxidant therapy, the local infusion of heparin,
and gene-directed therapy by adenoviral vectors,13-16 have
yet to be widely used and accepted. One possible impedi-
ment to the widespread use of these various therapies
shown to be effective in in vitro and in animal studies is
the expense, complexity, and the practical utility of applying
these therapies daily. Conversely, oxygen is widely available
and has a long history of relative safety. Oxygen, as a preven-
tive therapy for IH, has not been fully explored. The
primary aim of our study is to test the hypothesis that
30% supplemental oxygen will inhibit both SMCp and IH
at an AVF.
METHODS
All of the animal procedures in this study were con-
ducted in accordance with animal use protocols approved
by the University of Minnesota and the Minneapolis VA
Health Care System (MVAHCS) Institutional Animal
Care and Use Committees (IACUC).
Animal model. We chose 96 male New Zealand
White (NZW) rabbits (6-7 pounds; Bakkom Rabbitry,
Red Wing, Minn) for our animal model because we have
long used NZW rabbits in our studies on IH. Four rabbits
each were randomized into one of four experimental
groups that varied by six different time points (day 1, 3,
7, 21, 42, and 90):
d Group 1: control group—these rabbits had no surgery
and received no supplemental oxygen.
d Group 2: control group with oxygen—these rabbits
had no surgery but received supplemental oxygen.
d Group 3: AVF with no supplemental oxygen—these
rabbits underwent AVF placement but received no
supplemental oxygen.
d Group 4: AVF with supplemental oxygen—these
rabbits underwent AVF placement and received
supplemental oxygen.
Oxygen administration. Rabbits were assigned to the
control chamber (21% oxygen environment) or to the
oxygen chamber (30% oxygen environment). These cham-
bers were designed to regulate the environmental oxygen
content at 21% or 30%, maintain constant relative humidity
between 55% and 65%, and keep the ambient temperature
between 55F and 72F. All of the rabbits were condi-
tioned to the normoxic 21% oxygen environment chamber
for 1 week before the study and fed standard rabbit chowand water during the course of the study. Rabbits in the
supplemental oxygen groups were exposed to oxygen for
up to 42 days based on previous work completed in our
laboratory.6,9 The oxygen-supplemented rabbits were
exposed to a normoxic environment (21% oxygen) for
1 hour/d to allow for daily oxygen chamber care such as
food, water and bedding changes.
Creation of the AVF. After 1 week of acclimatization,
rabbits were anesthetized with ketamine (40 mg/kg) and
xylazine (5mg/kg) intramuscularly and intubated with
a 3-mm endotracheal tube. A 24-gauge intravenous cath-
eter was placed in the marginal ear vein and the rabbits
were placed on a circulating water heating pad to maintain
a normal core body temperature. Isoﬂurane (1%-1.5%)
inhalation anesthesia was used to maintain rabbits under
general anesthesia perioperatively.
Under loupe magniﬁcation and aseptic conditions,
a midline incision was used to expose the infrarenal aorta
and the left common iliac artery and vein. The rabbit was
heparinized with 200 U/kg of intravenous heparin 3
minutes before clamping the left common iliac artery and
vein proximally and distally. The iliac vein was transected
and the distal end oversewn. An arteriotomy was created
in the common iliac artery, and the iliac vein was anasto-
mosed to the iliac artery in an end-to-side manner with
two 7-0 Prolene (Ethicon, Somerville, NJ) sutures in
a running fashion from heel to toe (Fig 1). Blood loss
was replaced with intravenous normal saline.
Administration of 5-bromo-20-deoxyuridine and
vessel harvesting for histologic analysis. Tissue was eval-
uated from four rabbits in each group, at 1, 3, 7, 21, 42,
and 90 days. Tissue evaluation was performed at the
following ﬁve sites: ﬁstula, proximal artery, proximal vein,
distal artery, and distal vein. At 24 hours before the rabbits
were euthanized, 5-bromo-2’-deoxyuridine (BrdU; 100
mg/kg) was administered intraperitoneally. Rabbits were
euthanized with an overdose of pentobarbital.
After euthanasia, the right iliac artery and vein were
cannulated with 18-gauge catheters, and the iliac artery
was ﬂushed under physiologic pressures (80-100 mm
Hg) with normal saline while the venous catheter drained
the total body blood volume into an empty intravenous
bag. Once a clear efﬂuent was seen, the artery was perfu-
sion ﬁxed with Karnovsky’s solution for 10 minutes,17
and the vessels were harvested en bloc. The harvested spec-
imen was placed in 10% formalin and sent for histologic
preparation.
These specimens were placed in parafﬁn and sectioned
through the anastomosis for a total of nine sections, 5 mm
apart, for each vessel. The sections were individually
stained with (1) hematoxylin and eosin (routine his-
tology), (2) trichrome (stains collagen), (3) ﬁbrin (stains
thrombus), (4) Verhoeff-van Gieson (stains elastic ﬁbers),
(5) a-actin (stains SMCs), (6) anti-Factor VIII (stains
endothelial cells), (7) and anti-BrdU antibodies (to eval-
uate proliferation).
BrdU staining protocol. The BrdU staining was
performed using a Zymed BrdU staining kit (Zymed
Fig 1. Creation of the arteriovenous ﬁstula (AVF). A, Describes the normal anatomy of the iliac artery and vein and its
surrounding vessels. B, After clamping the left common iliac artery and vein proximally and distally, the iliac vein was
transected and the distal end oversewn. An arteriotomy was created in the common iliac artery, and the iliac vein was
anastomosed to iliac artery in an end-to-side manner. The artery proximal to the ﬁstula was considered the proximal
artery, and the artery distal to the ﬁstula was considered the distal artery. The vein immediately adjacent to the ﬁstula
was considered proximal vein and the vein distal to the ﬁstula was the distal vein. IVC, Inferior vena cava.
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facturer’s protocol. Each specimen was embedded in
parafﬁn, and 4-mm-thick sections were cut on a microtome.
Nine sections were cut transversely at each of the ﬁve sites,
and the Zymed protocol was subsequently followed without
modiﬁcation.
Morphometric analysis. Cells that incorporated
BrdU were identiﬁed as having a distinctive brown pigment
within their nuclei. A Zeiss microscope with a digitized
camera attachment (Oberkochen, Germany) fed images
directly into a personal computer-based microprocessor.
An image analysis (Bioquant 8.40.20 BQ-XI; Bioquant
Image Analysis Corp, Nashville, Tenn) morphometrics
program was used to count all BrdU-labeled cells and all
other cells within a microscopic ﬁeld. This process was
repeated until the entire circumference of the vessel wall
was evaluated. Cellular proliferation was deﬁned as all cells
positively staining for BrdU divided by all cells present
within the vessel wall. Cellular proliferation is reported in
percent units (positively stained BrdU cells/all cells).
The image analysis morphometrics program was also
used to calculate IH, which is reported as ratio of intimal
area (IA) to media area (MA). The digital camera was cali-
brated by measuring a known distance on the microscope
stage. The intimal and medial boundaries were marked,
and the IA and the MA were then automatically calculated.
The standardization of IA-to-MA ratio was performed to
eliminate any variation in ﬁxation and vessel size between
rabbits. The ﬁnal derivation of IH and SMCp werecalculated as an average of all nine sections from each of
the ﬁve sites.
Statistical analysis. All data are expressed as mean 6
standard error of the mean. Analysis of variance was used
for comparisons between three or more groups and the
Student two-tailed t-test was used for comparisons
between two groups. A P value of #.05 was considered
signiﬁcant.
RESULTS
There was no BrdU staining activity or intimal thick-
ness noted in group 1 or 2 at any recorded time point
(Figs 2 and 3).
For IH results, no change was seen in any group in
days 1 and 3 (Fig 2, A and B). There was a nonsigniﬁcant
increase in IH at all sites when comparing the nonoxygen-
supplemented surgical group (group 3) with the oxygen-
supplemented surgical group (group 4) on day 7 (Fig 2,
C). There was a signiﬁcant increase in IH at the proximal
and distal vein sites in group 3 compared with group 4,
whereas there were nonsigniﬁcant increases in IH at all
other sites when comparing group 3 with group 4 on day
21 (Fig 2, D). On days 42 and 90, there was a signiﬁcant
increase in IH at all locations in group 3 compared with
group 4 (Figs 2, E and F, and 4, A-D).
During SMCp evaluation, BrdU staining was not
increased in any group on day 1 (Fig 3, A). There was
a nonsigniﬁcant increase in staining noted at the AVF site
and at the distal vein site in group 3 compared with group
Fig 2. Effect of supplemental oxygen on intimal hyperplasia (IH) at the arteriovenous ﬁstula (AVF). A, No change in
IH with supplemental oxygen at day 1. B, No change in IH with supplemental oxygen at day 3. C, Supplemental
oxygen shows a trend toward inhibiting IH at all sites at day 7. D, Supplemental oxygen signiﬁcantly inhibits IH at the
proximal vein and distal vein at day 21. E, Supplemental oxygen inhibits IH at all sites at day 42. F, Supplemental
oxygen inhibits IH at all sites at day 90. Data are expressed as the ratio of intimal area (IA) to media area (MA). Data
are expressed as mean 6 standard error of the mean. P # .05 was considered signiﬁcant.
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was noted at all sites, except the proximal artery site, in
group 3 compared with group 4 on day 7 (Fig 3, C).
A signiﬁcant increase in was staining noted at the AVFand distal vein sites in group 3 compared with group 4,
whereas a nonsigniﬁcant increase was noted at all other
sites when group 3 was compared with group 4 on day
21 (Figs 3, D and 5, A-D). At days 42 and 90, there was
Fig 3. Effect of supplemental oxygen on smooth muscle cell proliferation (SMCp). A, No signiﬁcant proliferation was
observed on day 1 in any treatment group. On day (B) 3 and (C) 7, the arteriovenous ﬁstula (AVF) operation markedly
increased the 5-bromo-20-deoxyuridine (BrdU) staining, suggestive of proliferation at all sites. However, it was not
signiﬁcantly altered with oxygen supplementation.D,On day 21, the AVF operation markedly increased BrdU staining
at all sites, and this proliferation was signiﬁcantly decreased by oxygen supplementation at the site of the ﬁstula and the
distal vein. On day (E) 42 and (F) 90, there was no BrdU staining, suggesting absence of proliferation. This suggests
that SMCp is a self-limiting event. Data are expressed as percent units (positively stained BrdU cells/all cells). Data are
expressed as mean 6 standard error of the mean. P # .05 was considered signiﬁcant.
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Fig 4. Intimal hyperplasia (IH) at the distal vein. A and B, A 90-day nonoxygen-treated rabbit (hematoxylin and eosin
stain, original magniﬁcation, 100, 200). The yellow arrow represents the increased area of intima in a nonoxygen-
treated vein. C and D, A 90-day oxygen-treated rabbit (hematoxylin and eosin, original magniﬁcation, 100, 200).
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(Fig 3, E and F).
DISCUSSION
This study is the ﬁrst to demonstrate that the short-
term administration of 30% supplemental oxygen inhibits
the formation of IH and SMCp at the site of an AVF in
an animal model. We clearly demonstrate that IH begins
to develop not only at the site of an AVF but also in the
artery and vein proximal and distal to the AVF. IH begins
at day 7 and continues to increase through day 90 after
AVF placement in group 3. SMCp is ﬁrst noted at day 3,
persists through day 21, and is not noted at days 42 and
90. IH continues to increase in group 3 at all locations
through day 90, whereas BrdU staining peaks at day 21
and then is no longer present at days 42 or 90. However,
one of the limitations in this study includes the ability to
evaluate the changes in IH and SMCp along more contin-
uous time points, in particular between days 21 and 42 to
evaluate when SMCp proliferation stops.
Findings also support our hypothesis that IH and
SMCp are both inhibited by the administration of 30%
supplemental oxygen at all locations and at all time-
points. Interestingly, the data demonstrate that SMCp
begins early (day 3) and is self-limited, in that no SMCp
is noted after day 21 in group 3 or 4. These data also
demonstrate that IH only occurs after SMCp and IH
persists long after SMCp ceases. It would seem that the
process of IH, once started, continues without SMCpand may result in the pathologic vessel changes of IH
with clinical implications. Our data clearly show that 30%
supplemental oxygen will inhibit SMCp and IH and that
the effect persists long after the oxygen is discontinued.
These data deﬁnitively demonstrate that SMCp and IH
can be inhibited at the site of an AVF and at locations in
the artery proximal to the AVF and in the vein distal to
the AVF with the administration of low-dose (30%) supple-
mental oxygen for up to 21 days. The clinical and research
implications of these ﬁndings can be powerful.
After the National Kidney Foundation Kidney Disease
Outcomes Quality Initiative was published, a slow but
continuous change began in the standard of care for dialysis
access patients. The new standard of care, not only in the
United States but also worldwide, is that patients requiring
a surgical dialysis access procedure undergo placement of
an AVF ﬁrst as opposed to a prosthetic vascular access graft.
To date, much of the experimental research performed in
hemodialysis vascular access has been performed in
artery-to-graft or vein-to-graft anastomosis. Although we
have clinically noticed stenoses downstream of AVF, and
despite research evaluating the effects of hypoxia on veins,
the mechanisms underlying the formation of venous
stenosis in vascular anastomosis remain poorly understood.
Many factors have been hypothesized to be involved in the
formation of venous stenosis, including hypoxia. Hypoxia
activates several cytokines that are implicated in the angio-
genic process and has also been shown to be associated
with hemodialysis access failure.18 Our aim with this study
Fig 5. Cellular proliferation at arteriovenous ﬁstula (AVF). Immunoperoxidase staining of 5-bromo-20-deoxyur-
idine(BrdU)-labeled cells. The black arrows identify darkly stained nuclei, which represent BrdU-postive staining cells.
A and B, A 21-day nonoxygen-treated rabbit (biotinylated mouse anti-BrdU, original magniﬁcation, 100, 200).
C and D, A 21-day oxygen-treated rabbit (biotinylated mouse anti-BrdU, original magniﬁcation, 100, 200).
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oxygen in this AVF model. Our future studies will evaluate
and address the mechanism of processes we see in this
study.
Clinically, the data from this study would suggest that
SMC cellular activity is greatest between days 3 and 21
after creation of an AVF and that the administration of
30% supplemental oxygen for 21 days may be all that is
needed to inhibit the formation of IH at an AVF and its
adjacent artery and vein, thereby improving not only
patency and function of an AVF but also patient outcomes
and quality of life, while reducing health care costs.
With the reduction in time of administration and
concentration of oxygen, we can reduce the chance of expe-
riencing some problems that nasal cannula oxygen users
encounter, such as dry or bloody noses and skin irritation,
along with changes that could result from free oxygen radi-
cals that may result from the use of supplemental oxygen.
And in comparison with other therapies that last 3, 6, or
12 months, and even others that may be life-long, we think
that a minimum of 21 days of supplemental oxygen to treat
the burst of SMCp is relatively short term.
In addition, our ﬁndings add to the body of knowledge
already published by our laboratory that demonstrate the
key role oxygen plays in many forms of artery wall
pathology, including atherosclerosis, IH after the creation
of an artery-to-prosthetic vascular graft anastomosis, IHat the deployment of an intra-arterial stent, as well as
studies demonstrating an effect on veins. For a number
of years, our laboratory used 40% oxygen because other
studies have demonstrated that is a safe concentration,
and we reduced the oxygen to 30% to see if we could iden-
tify an optimal concentration. Our previous assumption
that 40% supplemental oxygen is required to mediate IH
and improve outcomes has been supplanted by the results
we have achieved using 30% supplemental oxygen.
CONCLUSIONS
We propose that areas for future research include
deﬁning the mechanisms underlying the ability of oxygen
to inhibit SMCp and reduce IH. Also, the exact duration
and concentration of supplemental oxygen needs to be
carefully deﬁned. Other animal models should be studied
to determine if the same results of controlling IH and
SMCp at the site of other arterial and venous interventions,
including at the deployment site of an intra-arterial stent,
are achieved.
Finally, a human clinical trial will be necessary to deter-
mine if these same effects are noted in the human model of
an AVF. Given the large numbers of ESRD patients who
undergo AVF placement, as well as the high failure of these
AVF secondary to IH, such a clinical trial is clearly feasible.
A shorter duration of treatment with lower oxygen concen-
trations would result in higher levels of patient compliance
JOURNAL OF VASCULAR SURGERY
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condition has widespread implications for a safe, cost-
effective treatment for patients undergoing all forms of
arterial and venous interventions.
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